Back in Person: Frontiers in Medicinal Chemistry 2023-Reference-Cited by-同舟云学术

Back in Person: Frontiers in Medicinal Chemistry 2023

Published:2023-07-24 Issue:19 Volume:18 Page:
ISSN:1860-7179
Container-title:ChemMedChem
language:en
Short-container-title:ChemMedChem

Author:

Gehringer Matthias¹^ORCID,Pape Felix²^ORCID,Méndez María³^ORCID,Barbie Philipp⁴,Unzue Lopez Andrea⁵,Lefranc Julien⁵^ORCID,Klingler Franca‐Maria⁶^ORCID,Hessler Gerhard⁷^ORCID,Langer Thierry⁸^ORCID,Diamanti Eleonora⁹,Schiedel Matthias¹⁰^ORCID

Affiliation:

1. Institute of Pharmaceutical Sciences Pharmaceutical/Medicinal Chemistry Department University of Tübingen Auf der Morgenstelle 8 72076 Tübingen Germany

2. NUVISAN Innovation Campus Berlin NUVISAN ICB GmbH Muellerstraße 178 13353 Berlin Germany

3. Sanofi R&D Integrated Drug Discovery Industriepark Höchst, Bldg. G838 65926 Frankfurt am Main Germany

4. Bayer AG R&D Pharmaceuticals Laboratory IV, Bldg. S106, 231 13342 Berlin Germany

5. Merck Healthcare KGaA Frankfurter Straße 250 64293 Darmstadt Germany

6. Isomorphic Labs Ltd. 100 New Bridge Street London EC4 V 6JA UK

7. Sanofi R&D Integrated Drug Discovery Industriepark Höchst, Bldg. G877 65926 Frankfurt am Main Germany

8. Department of Pharmaceutical Sciences University of Vienna Josef-Holaubek-Platz 2 1090 Vienna Austria

9. Department of Pharmacy and Biotechnology University of Bologna Via Belmeloro 6 40126 Bologna Italy

10. Institute of Medicinal and Pharmaceutical Chemistry Technische Universität Braunschweig Beethovenstraße 55 38106 Braunschweig Germany

Abstract

AbstractThe Frontiers in Medicinal Chemistry (FiMC) is the largest international Medicinal Chemistry conference in the German speaking area and took place from April 3rd to 5th 2023 in Vienna (Austria). Fortunately, after being cancelled in 2020 and two years (2021–2022) of entirely virtual meetings, due to the COVID‐19 pandemic, the FiMC could be held in a face‐to‐face format again. Organized by the Division of Medicinal Chemistry of the German Chemical Society (GDCh), the Division of Pharmaceutical and Medicinal Chemistry of the German Pharmaceutical Society (DPhG), together with the Division of Medicinal Chemistry of the Austrian Chemical Society (GÖCH), the Austrian Pharmaceutical Society (ÖPhG), and a local organization committee from the University of Vienna headed by Thierry Langer, the meeting brought together 260 participants from 21 countries. The program included 38 lectures by leading scientists from industry and academia as well as early career investigators. Moreover, 102 posters were presented in two highly interactive poster sessions.

Funder

Sanofi

Enamine

Merck

Idorsia Pharmaceuticals

Publisher

Wiley

Subject

Organic Chemistry,General Pharmacology, Toxicology and Pharmaceutics,Molecular Medicine,Drug Discovery,Biochemistry,Pharmacology

Reference104 articles.

1. Fragment Optimization of Reversible Binding to the Switch II Pocket on KRAS Leads to a Potent, In Vivo Active KRAS^G12C Inhibitor

2. A Study to Test Different Doses of BI 1823911 Alone and Combined With Other Medicines in People With Different Types of Advanced Cancer With KRAS Mutation - Full Text View -www.clinicaltrials.gov.

3. A First-in-human (FIH) Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors - Full Text View -www.clinicaltrials.gov.

4. Study on the Safety of Drug BAY2586116 and How it Works in Patients With Obstructive Sleep Apnea (a Sleep Disorder Caused by the Narrowing and Collapse of the Airway During Sleep) Including the Blood Level of the Drug and Effect of Its Doses and Routes of Administration - Full Text View -www.clinicaltrials.gov.